Abstract
Background: The search for new partner drugs to increase the therapeutic activity of existing antimalarial drugs is important because of decreased Plasmodium susceptibility. Amodiaquine (AQ) is an antimalarial drug. Moxifloxacin (MX) is a fluoroquinolone antibiotic with promising antiplasmodial activity. This study evaluated the benefit of MX as a partner drug with AQ for malaria treatment in Plasmodium berghei-infected mice. Methods: Adult Swiss albino mice (28-35g) of both sexes, randomly grouped and inoculated with Plasmodium berghei were used. The mice were treated orally with AQ (10 mg/kg), MX (6 mg/kg) and AQ-MX, respectively using the curative, prophylactic and suppressive protocols. Blood samples were collected and assessed for percentage parasitemia and hematological indices. Liver samples were assessed for histological changes. Mean survival time (MST) was observed in treated mice. Results: The curative, prophylactic and suppressive tests showed that AQ-MX decreased percentage parasitemia with difference observed at p
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
